BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Park KH, Yoo JJ, Kim SG, Kim YS. Fatal intratumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab: A case report. World J Clin Cases 2024; 12(22): 5177-5183 [PMID: 39109046 DOI: 10.12998/wjcc.v12.i22.5177]
URL: https://www.wjgnet.com/2307-8960/full/v12/i22/5177.htm
Number Citing Articles
1
Kazuhiro Tada, Shohei Yoshiya, Takaaki Mori, Ryoichi Narita, Kentaro Iwaki, Sota Nakamura, Yasunari Yamada, Hajime Takaki, Yo-ichi Yamashita, Kengo Fukuzawa. Tumor Rupture in a Patient with Recurrent Hepatocellular Carcinoma Following Atezolizumab plus Bevacizumab: A Case ReportSurgical Case Reports 2025; 11(1): n/a doi: 10.70352/scrj.cr.25-0331
2
Kazuya Murakawa, Fujimasa Tada, Atsushi Hiraoka, Hideko Ohama, Yuka Kimura, Ayaka Nakamura, Kana Matsuoka, Takuya Matsuda, Kanako Kato, Kei Onishi, Hirofumi Izumoto, Shogo Kitahata, Kozue Kanemitsu-Okada, Tomoe Kawamura, Taira Kuroda, Hideki Miyata, Eiji Tsubouchi, Hiroshi Sakaeda, Yoshiko Nakamura, Teruki Miyake, Masashi Hirooka, Tomoyuki Ninomiya, Yoichi Hiasa. Two cases of unresectable hepatocellular carcinoma with intratumoral aneurysm formation during atezolizumab/bevacizumab therapyKanzo 2025; 66(9): 397 doi: 10.2957/kanzo.66.397
3
Multiple drugsReactions Weekly 2024; 2019(1): 337 doi: 10.1007/s40278-024-64250-1
4
Zhihong Chen, Junwei Zhang, Lei Zhang, Yaoge Liu, Ting Zhang, Xinting Sang, Yiyao Xu, Xin Lu. Evaluation of immune checkpoint inhibitor-associated hepatotoxic adverse events: A pharmacovigilance analysis based on the FAERS databaseInternational Journal of Immunopathology and Pharmacology 2025; 39 doi: 10.1177/03946320251343943
5
Mina Tharwat, Ahmed Tawheed, Mohamed El-Kassas. Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studiesWorld Journal of Clinical Cases 2025; 13(9): 99043 doi: 10.12998/wjcc.v13.i9.99043